Artificial intelligence (AI) continues to play a significant role in addressing many of the core challenges currently faced by the pharmaceutical industry.
The coming years will be more about practical uses of AI, as businesses ensure they get their money’s worth by using AI to address specific use cases, not least of which will be seen in the pharma industry.  
Though it is a highly regulated industry and has historically been slow to adopt new technologies and modernise, pharma companies using AI are leading the charge despite such hurdles and changing the industry landscape.  
With many benefits already being enjoyed, the use of AI in the pharma industry, as well as in the healthcare space overall, is expected to continue to increase in the next five years. 
The applications of AI in healthcare and pharma are many, with the potential to transform key aspects of the industry and drive innovation.  
Industry investment: pharmaceuticals companies using AI 
GlobalData forecasts that the market for AI platforms for the entire healthcare industry will reach $4.3bn by 2024, up from $1.5bn in 2019.  
This will be driven pharma companies using AI, as well as healthcare providers and payers, with the forecast to reach $2.9bn by 2024. 
VÍøÆØÃÅ pharma AI companies have invested time, money and resources in developing their bespoke artificial intelligence solutions. Each solution is designed to disrupt the pharmaceutical industry while simultaneously addressing current difficulties.
Discover the leading artificial intelligence companies in the pharmaceutical industry
Using its experience in the sector, Pharmaceutical Technology has listed some of the leading companies providing products and services related to AI.
The information provided in the download document is drafted for pharmaceutical executives and technology leaders involved in AI pharma solutions.
The download contains detailed information on suppliers and their product offerings, alongside contact details to aid purchase or hiring decisions.
Amongst the leading AI in pharma suppliers are Atomwise, , Cyclica, , Recursion, Iktos, Auransa, and InveniAI.
Examples of artificial intelligence used in pharma 
When utilising the wide range of practical applications available, pharma companies using AI have the potential to transform key aspects of the industry while simultaneously driving innovation. 
Among these uses are data management, drug discovery, and clinical trial design. 
Such a range allows for both industry growth, as well as important clinical advances in real, practical terms.  
GlobalData experts have estimated, with detailed and data-led forecasts, that the market for AI platforms for the entire healthcare industry will reach $4.3bn by 2024, an increase from $1.5bn in 2019.  
Such growth will be mainly driven by major, leading pharma companies using AI in a range of applications. Ultimately, is forecast to reach $2.9bn by 2024.
Real-world applications of AI in pharma 
With many examples of pharmaceutical companies using AI, we can observe real-world applications of the technology. From drug discovery to mental health innovation, real-world applications are having a sizeable impact on both health and company values.  
Areas impacted include improved decision-making, reduced manual groundwork, and the improvement of pharma and healthcare systems across several areas in the healthcare sector. 
Drug discovery 
Pharma companies using AI are assisting in the research phase of drug development by analysing existing materials, publications, data and insights. 
Drug sales 
Using AI in the analysis of vast amounts of clinical data and returning actionable insights, reducing time spent on sales research. 
Optimisation of clinical trials 
Assessing clinical trial data, optimisation of patient matching and the design of clinical trials.
FAQs
How is AI transforming the pharmaceutical industry?
AI is transforming the pharmaceutical industry by enhancing drug discovery, improving clinical trials, and streamlining data analysis. It speeds up the identification of potential drug candidates, optimises trial designs, and helps in data-driven decision-making across the drug development process.
What are the benefits of using AI in drug discovery?
AI enables faster, more cost-effective drug discovery by analysing vast datasets, identifying novel compounds, and predicting biological interactions, leading to more efficient development pipelines and reduced time to market.
How does AI optimise clinical trials?
AI assists in clinical trials by improving patient recruitment, monitoring real-time trial data, and predicting outcomes, resulting in more targeted and efficient trials with better success rates.
Which companies are leading AI innovation in pharma?
VÍøÆØÃÅ companies include Atomwise, BenevolentAI, Exscientia, and Recursion, which offer AI-driven platforms for drug discovery, development, and personalised medicine.
What role does AI play in personalised medicine?
AI helps personalise treatment plans by analysing patient data to predict how individuals will respond to certain medications, enabling more tailored and effective therapies.
(See below for more FAQs).
For full details (including contact details) on the leading companies within this space, download the free Buyer’s Guide below:
Frequently asked questions
-
How is artificial intelligence transforming drug discovery in the pharmaceutical industry?
Artificial intelligence (AI) is revolutionising drug discovery by enabling the rapid analysis of vast datasets to identify potential drug candidates more efficiently than traditional methods. AI algorithms can predict how different compounds will interact with biological targets, significantly reducing the time and cost associated with bringing new drugs to market. For example, companies like Insilico Medicine have utilised AI to design potential new drugs, one of which showed promising initial results in preclinical studies. ​
-
How is AI improving personalised medicine in the pharmaceutical industry?
AI is playing a transformative role in personalised medicine by enabling the development of treatments tailored to individual patients. By analysing genetic data, lifestyle factors, and medical histories, AI algorithms can identify the most effective drug formulations for specific patient groups. Machine learning models can predict how individuals will respond to different treatments, reducing trial and error in prescribing medication. This leads to more targeted therapies, minimising side effects and improving patient outcomes. AI is also being used to develop precision oncology treatments, where cancer therapies are designed based on a patient’s genetic mutations, significantly enhancing the effectiveness of treatment.
-
What impact does AI have on pharmaceutical supply chain management?
AI is streamlining pharmaceutical supply chains by improving forecasting, logistics, and demand planning. Predictive analytics powered by AI can assess historical sales data, seasonal trends, and real-time market conditions to optimise inventory levels. This minimises waste, prevents drug shortages, and ensures that life-saving medicines reach patients when needed. AI-driven automation is also enhancing quality control by detecting inconsistencies in manufacturing processes before they lead to product recalls. Additionally, AI improves security by identifying potential counterfeit drugs in the supply chain, protecting patients from unsafe medications.
-
How is AI helping to repurpose existing drugs for new treatments?
AI is accelerating drug repurposing by analysing vast datasets to uncover new therapeutic uses for existing medications. Traditional drug discovery can take over a decade, but AI-driven approaches significantly shorten this timeline by identifying drugs with previously unrecognised potential. AI scans scientific literature, clinical trial results, and patient data to detect patterns indicating that an approved drug may be effective against another disease. This has already led to breakthroughs, such as identifying existing drugs for treating rare diseases or repurposing antiviral medications for new infectious diseases. Pharmaceutical companies are increasingly leveraging AI for drug repurposing as it offers a cost-effective and efficient alternative to developing new drugs from scratch.
-
What role does AI play in detecting and mitigating adverse drug reactions?
AI is improving pharmacovigilance by rapidly detecting adverse drug reactions (ADRs) and mitigating risks to patient safety. Machine learning models analyse electronic health records, patient reports, and social media data to identify early warning signs of negative drug interactions. AI can detect subtle correlations that may be overlooked in traditional monitoring, allowing for faster intervention. Additionally, natural language processing (NLP) enables AI to extract insights from medical literature and adverse event reports, improving the identification of potential safety concerns. This proactive approach ensures that pharmaceutical companies can respond quickly to emerging risks and improve drug safety.
-
How is AI shaping the future of pharmaceutical research and development?
AI is fundamentally reshaping pharmaceutical R&D by enhancing efficiency, reducing costs, and driving innovation. AI-powered simulations can model complex biological interactions, allowing researchers to test hypotheses without relying solely on costly laboratory experiments. Deep learning algorithms help identify novel drug candidates by analysing vast chemical and genetic datasets. AI is also being used to optimise clinical trial designs by predicting patient responses, selecting ideal trial locations, and automating data collection. In the future, AI is expected to enable fully autonomous drug discovery platforms, drastically reducing the time needed to bring new medicines to market. The integration of AI is not just accelerating research but also making drug development more precise and data-driven.